Abstract
Background
Community consultation and public disclosure are key components of exception from informed consent (EFIC) trials, and mandated by the US Department of Health and Human Services (DHHS) and the Food and Drug Administration (FDA). However, it is not known how demographic characteristics of community members impact their willingness to participate in such studies. The purpose of this study was to evaluate the demographics of community members regarding their attitudes towards participation in an EFIC trial; participation of relatives in such a trial; the need for emergency medical research; and, the execution of the trial in their community. This analysis is focused on the minority of individuals who have unfavorable views towards participation and emergency care research so that we can better understand their needs and concerns.
Methods
Multinomial logistic regression analysis of responses to a survey distributed as part of the community consultation campaigns for a large, multicenter EFIC trial in trauma patients. The surveys were distributed to community members in the catchment areas of 77 trauma centers.
Results
A total of 88,711 responses to four separate survey questions were received and analyzed, along with demographics of the survey respondents. 13,201 of 22,441 respondents (58.8%) indicated they would want to be entered in the trial. 3,625 (16.2%) responded they would not want to be enrolled and 5,615 (25.1%) responded “I don’t know” or “I don’t want to answer”. 19,430 of 22,329 (87.0%) responded they believe that emergency medical research was necessary and 19,555 of 22,324 (87.6%) believed that this study should be done in their community. Individuals who responded “No” or “I don’t know”’ to the questions were younger, female, non-white, had a lower education level, and unknown or lower household income. The pattern was broadly similar for people who responded “I don’t know” or “I don’t want to answer”, albeit with some differences.
Conclusions
Community consultation is a key component of establishing trust with the community in which a given study will be conducted. Understanding which individuals, or groups of individuals, are reluctant to engage is important.
Similar content being viewed by others
Background
Consent is a cornerstone of ethical research, but when patients have serious injuries, they – and their Legally Authorized Representatives (LAR) – are often unable to participate in the informed consent process. In 1996, the US Department of Health and Human Services (DHHS) and the Food and Drug Administration (FDA) issued guidelines for the conduct of clinical trials in patients with emergent medical conditions [1], including processes for community consultation and public disclosure (CC/PD). Community Consultation is a process that primarily involves consultation between the investigative team and representatives of the communities, overseen and informed by feedback from the institutional review board (IRB), where the relevant “community” includes people residing in the geographical area where the research will be conducted and communities likely to have or at-risk for the condition [2, 3].
Many previous studies of CC, including a systematic review, have demonstrated that respondents support emergency care research [4,5,6,7,8]. The literature on the respondent characteristics associated with specific attitudes and responses, in contrast, is much more limited. Biros et al. showed that those with higher education or incomes were favorably inclined or tended to be favorable towards research in general, and EFIC research in particular, whereas those with less education and older individuals were not supportive. They also observed that women tended to be less supportive, although this finding was not statistically significant. [5] Ross et al. studied willingness to participate in an EFIC trial in pediatric intensive care found that willingness rates varied by race. [6] Both of these studies were small, which may have obscured differences.
The Center for Injury Science at the University of Alabama at Birmingham (UAB) uses an interactive media based approach to CC, which consists of social media communications on Facebook and Instagram, linked websites, online community forums, and targeted community surveys [9,10,11,12]. The community surveys solicit community members’ opinions on whether they would want to be enrolled in a proposed study, whether they would want a family member to be enrolled, whether they regard emergency care research as important, and whether they think the proposed study should be conducted in their community. Along with these results, the surveys collect demographic information, including age, gender, race/ethnicity, education level, household size, and household income.
This interactive media based approach was used to conduct CC activities for the Trauma And Prothrombin Complex Concentrate (TAP) trial, a randomized clinical trial that compares the early administration of 4-Factor Prothrombin Complex Concentrate with placebo, in trauma patients predicted to require a large volume blood transfusion [13]. The trial, which is sponsored by CSL Behring, was being conducted in approximately 120 trauma centers. Approximately 95 of the sites were located in the United States and therefore required to conduct CC/PD, making this one of the largest CC/PD campaigns conducted to date.
We have reported the overall results of the TAP trial CC/PD in a previous publication, with emphasis on reach, as well as similarities and differences between sites in terms of website views, survey responses, community forum attendance, and opt-out requests [4, 14]. The scope of the TAP trial CC/PD permits a much more comprehensive analysis of the characteristics of respondents who agree, or disagree, to participate in EFIC trials. The purpose of this present analysis was, therefore, to evaluate the social and demographic factors associated with survey respondents’ willingness to participate in the trial, in order to facilitate the further development of CC/PD methods for multicenter exception-from-informed-consent (EFIC) trials.
Methods
Community surveys
The survey consisted of six questions (supplementary file 1), designed to evaluate respondents’ willingness to be enrolled in the TAP trial without consent if incapacitated (question 1); respondents’ willingness for family members to be enrolled in the TAP trial without consent if incapacitated (question 3); whether they believe that emergency medical research is necessary (question 5), and whether they believe that the TAP trial should be done in their community (question 6). The responses to questions 2 and 4, which relate to reasons why they would not want to be included, and were conditional of “no” answers to questions 1 and 3 respectively, were not included in this analysis. Supplementary file 1 also lists the answer choices.
The surveys were administered using Qualtrics (Qualtrics, Seattle, WA), using the company’s cloud-based survey software platform. The surveys were accessible to anyone, from the TAP trial websites, from a QR code on a study handout that sites placed in areas where they felt they could reach at-risk or underserved community members, or directly, using a browser. In addition, invitations to complete the surveys were distributed, by Qualtrics, to individuals who reside in counties in the catchment area of participating trauma centers. We aimed to have at least 300 completed surveys from each participating trial site. The surveys were completed between October 20th, 2022 and November 14th, 2023.
Outcomes
Questions 1, 3 and 5 had four answer choices – “Yes”, “No”, “I don’t know”, and “I don’t want to answer”. We excluded the “I don’t want to answer”(1.97%) responses from the analysis. Questions 6 had two answer choices, “Yes” and “No”.
Analysis
We used a multinomial logistic regression model for questions 1, 3, and 5 and a binomial logistic model for question 6 to estimate odds ratios (ORs) and associated 95% confidence intervals (95% CIs) to examine whether the demographic characteristics associated with answering “Yes”, “No”, or “I don’t know” differed. We modeled answer choices using a random utilities model in which individuals faced three choices: Agreement (I would want to be enrolled; I would want family members to be enrolled; I believe that emergency medical research is necessary; I believe that the study should be done in my community), disagreement (I would not want to be enrolled; I would not want family members to be enrolled; I do not believe that emergency medical research is necessary; I do not believe that the study should be done in my community), and uncertainty (I don’t know if I would want to be enrolled; I don’t know if I would want family members to be enrolled; I don’t know if emergency medical research is necessary). The utilities associated with each of these choices were modelled as a function of individual specific demographic characteristics. The analysis was performed in SAS v9.4.
Results
The responses to each of the questions are shown in Table 1. In total, there were 22,441 responses to question 1; 21,617 to question 3; 22,329 to question 5; and 22,324 to question 6. (Please note that these numbers differ from our previous publication, which only included 52 trial sites, whereas the present analysis includes data from 77 centers.)
The majority of those surveyed responded that they would want to be entered into the TAP trial, even if they could not give consent (13,201; 58.8%), that they would want family members to be entered (12,174; 56.3%), and that emergency medical research was necessary (19,430; 87.0%). Respectively, 3,625 (16.2%), 3,885 (18.0%), and 906 (4.1%) replied that they would not want be entered; and 4,903 (21.9%), 4,814 (22.3%), and 1,700 (7.6%) replied that they did not know if they would want to be entered. With regards to question 6 (“Do you believe that this study should be done in your community?”), which did not include an “I don’t know” answer choice, 19,555 (87.6%) responded “yes”, and 2,769 (12.4%) “no”. Table 1 also lists the number of “I don’t want to answer” responses, which were excluded from the subsequent analyses.
Tables 2– 5 present the weighted sample means by outcome (“Yes”, “No”, “I don’t know”), and the results of the multinomial logit model. In each of the tables, the first column shows the characteristics of the “Yes” respondents, as number and percentage, for categorical and ordinal outcomes; or mean and standard deviation, for continuous outcomes. Subsequent pairs of columns show the results for the “No” and “I don’t know” respondents, compared to the “Yes” respondents. In each case, the first column shows the raw data, and the second the odds ratios (OR) and associated 95% confidence intervals. Values > 1 indicates that higher values of the explanatory variable increase the predicted probability of the first relative to the second outcome. For the categorical and ordinal characteristics, a referent was chosen. For example, the odds of being female (rather than male) for those who responded that they would not want to be entered into the trial, compared with those that did, were 1.13 (95% CI 1.05–1.22).
For question 1 (“If you were severely injured and needed blood transfusions, would you want to be entered into this research study, even though you couldn’t give consent?”), those who responded “No”, compared to those who responded “Yes”, were more likely to be younger, female, non-white and non-Hispanic, have an education level lower than high-school, and a household income of less than $80,000). Those who responded “I don’t know”, compared to those who responded “Yes”, were more likely to be older, non-male, multi-racial and non-Hispanic, have an education level lower than high-school, and have an income of less than $35,000. (Table 2).
For question 3 (“If one of your family members was severely injured and needed blood transfusions, would you want them to be entered into this research study, even if they or you couldn’t give consent?”), those who responded “No”, compared to those who responded “Yes”, were more likely to be younger, non-male, non-White, have an education level lower than high-school, and have a household income of less than $100,000. Those who responded “I don’t know”, compared to those who responded “Yes”, were more likely to be older; non-male; Asian alone or multiracial, non-Hispanic; have a less-than-high-school education or some college education, and have an income of less than $50,000. (Table 3).
For question 5 (“Do you believe that emergency medical research is necessary?”), those who responded “No”, compared to those who responded “Yes”, were more likely to be younger, non-male, non-white, have an education level lower than high-school, and have an income of less than $80,000. Those who responded “I don’t know”, compared to those who responded “Yes”, were more likely to be non-male, non-white, have a less-than-high-school education, and have an income of less than $65,000. (Table 4).
For question 6 (“Do you believe that this study should be done in your community?”), those who responded “No”, compared to those who responded “Yes”, were more likely to be younger, non-binary/gender-nonconforming, none-white, have an education level lower than high-school, and have an income of less than $80,000. (Table 5).
The relationship between individuals’ age, income, and education level, and their willingness to participate, is shown in a series of stacked contour graphs. These graphs illustrate how different characteristics interact and impact individuals’ opinions. Supplementary Fig. 1 shows the probability of a “yes”, “no”, or “I don’t know” response, with reference to age and household income, to the four questions. Supplementary Fig. 2 shows the probability with reference to age and educational attainment. Darker colors indicate a lower probability.
Discussion
We have previously shown that our interactive, media-based approach to community consultation and public disclosure reaches large numbers of individuals, through the use of social media [9]. However, exception from informed consent regulations emphasize consultation with the community, which requires the solicitation of opinions.
In a socially just world, individuals should have equal opportunities to share their views. Encouragingly, our present analysis shows that community members who completed our surveys are racially, ethnically, educationally, and economically diverse. It is conceivable that the online distribution of the community surveys provides opportunities for otherwise underrepresented populations who might not be reached through traditional means of community outreach to learn about complex healthcare issues affecting their communities, and to offer their opinions.
Our results show that the majority of individuals would want to be enrolled in an EFIC clinical trial or have their family member enrolled in such a trial when they are in a life-threatening emergency situation. As well, the majority of the survey participants agreed that emergency research with an exception from informed consent is important to conduct. These findings are in keeping with previous research [5,6,7,8, 15, 16]. Our results, however, also show that not everyone is willing to participate in the TAP trial. There is little previous research on how demographics impact individuals’ opinions of such studies, and their willingness to participate, or for their family members to participate. Our study, which is much larger than the two previous studies [5, 6], identifies clear patterns in a large and diverse patient population. We found that the patient group which tended to select “no”, or were unsure about participation, tended to be younger, non-male, non-white, have a lower education level, and an unknown or lower household income. These results are in keeping with the studies by Biros and Ross [5, 6], and affirm that social and demographic factors play an important role in community healthcare initiatives. However, like previous work, our study cannot shed light on the reasons for these differences.
Interestingly, when we asked broader questions about the community as a whole (“Do you believe that emergency medical research is necessary?” and “Do you believe that this study should be done in your community?”), responses were more favorable than those received in response to questions about individual willingness to participate. Again, these findings are in keeping with previous work [8].
It is possible that the results reflect genuine differences in opinions, which individuals are entitled to, and should be respected. Anyone could request to opt out of the TAP trial, should they be injured. However, there is also a possibility that those who selected no, I don’t know or I don’t want to answer, might benefit from more detailed or better explanations of why a particular study is being done, and more information about EFIC regulations and overall study risks and benefits.
There are many types of social activities that are good for society, or the community at large, but that inconvenience the individual or puts them at risk. The dichotomy between agentic (advancing one’s self) and communal motives (serving others) is widely known [17]. It is plausible that people might both want the research to be done, but would prefer that they not be the ones participating in the trial.
Other forms of community outreach during the community consultation and public disclosure did not see similar feedback from this specific demographic. Online forums are relatively easily directed towards certain groups. However, we have previously shown that engagement with these types of community meetings is low. Furthermore, those who are opposed to EFIC research may also not be prepared to participate in community meetings, making this approach problematic. Targeting social media communications towards certain geographic areas and age groups is also possible and straightforward. Targeting certain racial or ethnic groups, in contrast, is no longer possible, following the inappropriate use of such data [18,19,20].
Our findings have practical and ethical implications and will require examination by ethicists, regulators, investigators, sponsors and regulators. The investigators’ role is to “consult with the community”, which is defined as a bidirectional process that requires the provision of information and the solicitation of opinions. This definition would appear to support the idea of increased engagement with communities that exhibit increased hesitancy. However, it should be noted that the EFIC regulations do not stipulate a certain level of agreement within a community. Therefore, such activities should be less about changing opinions and more about increased engagement and outreach with better communication of relevant information without being coercive. Beyond community consultation, our study should also prompt investigators to examine how discussions with patients – once they have been enrolled, under EFIC regulations – are conducted, with reference to the demographic characteristics identified. This knowledge may help to guide such conversations, and better address individuals’ concerns.
This study is, to our knowledge, the largest analysis of the social and demographic characteristics of individuals taking part in a community consultation for an EFIC study. It included 22,441 responses – more than then ten times the number in the study by Biros et al [5] – and therefore provides a highly granular picture, with tight confidence intervals. However, it also has limitations. Not all EFIC studies are the same, and respondents’ opinions may vary depending on the type of treatment under investigation. These differences are worthy of further study. Furthermore, our study did not include geography as a possible factor. For example, the opinions of people who live in San Francisco may differ from those in Houston. This will require further investigation. Lastly, the method of survey distribution is important. Obtaining large numbers of “organic” responses (those submitted by individuals who found their own way to the survey website, from the trial website) is difficult, given the large number of requests for opinions that individuals receive every day by social media, email, or otherwise. This type of “consultation fatigue” is increasingly recognized. We therefore use a survey company that maintains extensive lists of individuals, in known locations, who complete surveys for a fee. It is not known how representative this group of survey-takers is or if this population may be biased in some way and this is a further area of investigation.
Our data shows that it is worth continuing to explore the reasons for certain demographics of people to resist or hesitate to be a part of exception from informed consent trials, so that appropriate remedies can be implemented to make community consultation more informative and effective for such groups. Engaging communities with sensitivity and humility can help investigators build trust with hesitant groups by showing respect and willingness to listen, which may foster long-term trust.
Conclusions
Exception from Informed Consent trials are, rightly, highly scrutinized. Community consultation is a key component of establishing trust with the community in which a given study will be conducted. Understanding which individuals, or groups of individuals, are reluctant to engage is important. We recognize that disadvantaged communities often experience a greater burden of injustice; therefore, researchers should make concerted efforts to ensure adequate representation of these groups are met. Lastly, more work is required to better understand how digital inequities could possibly contribute to underrepresented community groups and how better to address these structural biases. Everyone deserves an equal opportunity to learn about research that is occurring in their communities.
Data availability
The data that support the findings of this study may be available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Abbreviations
- CC:
-
Community Consultation
- CC/PD:
-
Community Consultation and Public Disclosure
- CI:
-
Confidence Interval
- DHHS:
-
Department of Health and Human Services
- EFIC:
-
Exception-from-informed-consent
- FDA:
-
Food and Drug Administration
- IRB:
-
Institutional Review Board
- LAR:
-
Legally Authorized Representative
- OR:
-
Odds Ratio
- PD:
-
Public Disclosure
- UAB:
-
University of Alabama at Birmingham
- TAP:
-
Trauma And Prothrombin Complex Concentrate trial
References
Food and Drug Administration (FDA). Exception from informed consent requirements for emergency research (21 CFR 50.24). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50/subpart-B/section-50.24. Cited 2024 July 3.
Dickert N, Sugarman J. Ethical goals of community consultation in research. Am J Public Health. 2005;95(7):1123–7.
Tisherman SA. Defining “Community” and “Consultation” for Emergency Research that Requires an Exception from Informed Consent. AMA J Ethics. 2018;20(5):467–74.
Stephens SW, Carroll-Ledbetter C, Duckert S, Coffman T, Nelson M, Brown KN, et al. Interactive Media-Based Approach for an Exception From Informed Consent Trial Involving Patients With Trauma. JAMA Surg. 2024. Available from: https://jamanetwork.com/journals/jamasurgery/fullarticle/2820787. Cited 2024 July 3.
Biros MH, Sargent C, Miller K. Community attitudes towards emergency research and exception from informed consent. Resuscitation. 2009;80(12):1382–7.
Ross CE, Asad M, Kundun H, Gathers CL, Berg RA, Kleinman ME. Willingness to participate in an active exception from informed consent trial in the pediatric intensive care unit. Acad Emerg Med. 2024;31(11):1188–91.
Stephens SW, Williams C, Gray R, Kerby JD, Wang HE. Preliminary experience with social media for community consultation and public disclosure in exception from informed consent trials. Circulation. 2013;128(3):267–70.
Feldman WB, Hey SP, Franklin JM, Kesselheim AS. Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys. JAMA Netw Open. 2019;2(7):e197591.
Stephens SW, Carroll-Ledbetter C, Duckert S, Coffman T, Nelson M, Brown KN, et al. Interactive media-based approach for an exception from informed consent trial involving patients with trauma. JAMA Surg. 2024. https://doi.org/10.1001/jamasurg.2024.2147.
Stephens SW, Williams C, Gray R, Kerby JD, Wang HE, Bosarge PL. Using social media for community consultation and public disclosure in exception from informed consent trials. J Trauma Acute Care Surg. 2016;80(6):1005–9.
Farley P, Stephens SW, Crowley B, Collins SP, Wong MD, Panas AB, et al. Exception from informed consent trials: social-media-based community consultation campaigns are representative of target communities. Trauma Surg Acute Care Open. 2021;6(1):e000830.
Jansen JO, Stephens SW, Crowley B, Inaba K, Goldkind SF, Holcomb JB. Interactive media-based community consultation for exception from informed consent trials: how representative should (and can) it be? J Trauma Acute Care Surg. 2022;92(3):e41–6.
Trauma and PCC (TAP) Study. Available from: https://clinicaltrials.gov/study/NCT05568888. Cited 2026 February 6.
Stephens SW, Carroll-Ledbetter CR, Duckert S, Coffman TW, Nelson MA, Rodgers J, et al. Analysis of time to regulatory approval in an exception from informed consent trial in trauma patients. J Trauma Acute Care Surg. 2025;98:492–9.
Sims CA, Isserman JA, Holena D, Sundaram LM, Tolstoy N, Greer S, et al. Exception from informed consent for emergency research: consulting the trauma community. J Trauma Acute Care Surg. 2013;74(1):157–66.
Govindarajan P, Dickert NW, Meeker M, De Souza N, Harney D, Hemphill CJ, et al. Emergency Research: Using Exception from Informed Consent, Evaluation of Community Consultations. Acad Emerg Med 20 1 98–103. J Adams editor.
Lawford HL, Ramey HL. Predictors of early community involvement: advancing the self and caring for others. Am J Community Psychol. 2017;59(1–2):133–43.
Layug A, Krishnamurthy S, McKenzie R, Feng B. The Impacts of Social Media Use and Online Racial Discrimination on Asian American Mental Health: Cross-sectional Survey in the United States During COVID-19. JMIR Form Res. 2022;6(9):e38589.
Tiwari P. Misuse of Personal Data by Social Media Giants. Jus Corpus Law Journal. 2023;3(2):1041–64.
Soussan T, Trovati M. Social Media Data Misuse. In: Barolli L, Chen HC, Miwa H, editors. Advances in Intelligent Networking and Collaborative Systems. Cham: Springer International Publishing; 2022. p. 183–9.
Acknowledgements
Not applicable.
The TAP trial investigators include:
Dr. Daniel Cox, University of Alabama at Birmingham Hospital (UAB)
Dr. Charles Hu, Chandler Regional Medical Center (Dignity Health Chandler Regional Medical Center)
Dr. Jordan Weinberg, Dignity Health St. Joseph's Hospital and Medical Center
Dr. Thomas Wertin, Valleywise Health Medical Center
Dr. Amer Afaneh, Mercy Health—St Vincent Medical Center
Dr. Saman Arbabi, Harborview Medical Center (UW Medicine—Harborview Medical Center)
Dr. Grant Bochicchio, Barnes-Jewish Hospital (Washington University School of Medicine in St. Louis)
Dr. Tanya Anand, University of Arizona Tucson (University of Arizona College of Medicine—Tucson)
Dr. Chad Wilson, Baylor University Medical Center/Ben Taub General Hospital (Baylor College)
Dr. Yuri Rojavin, Capital Health Regional Medical Center
Dr. Samuel Wade Ross, Atrium Health Carolinas Medicine
Dr. Paul Bjordahl, Sanford Health (SD)
Dr. Stephanie Lueckel, Rhode Island Hospital
Dr. Lewis Jacobson, Ascension St. Vincent Hospital
Dr. Terence O’Keeffe, Augusta University Medical Center
Dr. Uroghupatei Iyegha, HealthPartners Institute
Dr. Suresh “Mitu” Agarwal, Duke University Hospital (Duke University Medical Center)
Dr. Adrian Maung, Yale School of Medicine
Dr. Kyle Kalkwarf, University of Arkansas Medical Sciences Medical Center (UAMS)
Dr. Caleb Butts, University of South Alabama (USA Health University Hospital)
Dr. Richard George, Summa Akron City Hospital
Dr. Timothy Stevens, Northeast Georgia Medical Center—Gainesville
Dr. Khaled Zreik, Sanford Health (ND)
Dr. Jeffrey H. Anderson, Temple University Health System
Dr. Brian Driver, Hennepin Healthcare
Dr. Martin Schreiber, Oregon Health and Sciences University Hospital (Trunkey Center)
Dr. Jonathan Meizoso, Ryder Trauma Center
Dr. Michael Goodman, University of Cincinnati Medical Center
Dr. Jason Hoth, Wake Forest University Health Sciences (Atrium Health Wake Forest Baptist)
Dr. Navdeep Samra, Ochsner University Health Shreveport—Academic Medical Center (LSU)
Dr. David Machado-Aranda, Ronald Reagan University of California Los Angeles Medical Center (UCLA)
Dr. Jeffrey Claridge, Metrohealth Hospital systems
Dr. Joseph DuBose, Dell Seton Ascension (University Medical Center Brackenridge) (Dell Seton Medical Center)
Dr. Alisa Cross, OU Health—University of Oklahoma Medical Center
Dr. Dennis Ashley, Mercer University School of Medicine/Medical Center of Central Georgia (Atrium Health Navicent)
Dr. Rajesh Gandhi, JPS Health Network
Dr. Christine Leeper, University of Pittsburgh Medical Center Presbyterian
Dr. James Bardes, West Virginia University
Dr. Jeff Nahmias, UC Irvine Medical Center (UCI Center for Clinical Research)
Dr. Elizabeth Benjamin, Grady Memorial Hospital (Grady Health System) EMORY
Dr. Jeremy Cannon, University of Pennsylvania-PPMC (Penn Presbyterian Medical Center)
Dr. John Kepros, HonorHealth
Dr. Sarah Majercik, Intermountain Medical Center
Dr. Thomas Schroeppel, UCHealth Memorial Health System
Dr. Warren Dorlac, Medical Center of the Rockies
Dr. Nikolay Bugaev, Tufts Medical Center
Dr. Raul Coimbra, Riverside University Health System Medical Center
Dr. Don Jenkins, University Health System (University of Texas Health San Antonio and University Health)
Dr. Jon Wisler, The Ohio State University Wexner Medical Center
Dr. Katherine McKenzie, Jamaica Hospital Medical Center
Dr. Matthew Kutcher, University of Mississippi Medical Center
Dr. Margo Carlin, University Medical Center of El Paso
Dr. Natasha Keric, Banner University Medical Center Phoenix
Dr. Robert Maxwell, Erlanger Health System
Dr. Marc DeMoya, Froedtert Memorial Lutheran Hospital
Dr. Babak Sarani, George Washington University Hospital
Dr. Jay Doucet, UC San Diego Health
Dr. Juan Duchesne, University Medical Center New Orleans LCMC Health (Tulane University School of Medicine)
Dr. Michael Cripps, University of Colorado Anschutz Medical Center
Dr. Patrick W. McGonagill, University of Iowa Hospital & Clinics
Dr. Lena Napolitano, University of Michigan
Dr. Kevin Kemp, University of Nebraska Medical Center
Dr. Brian Daley, University of Tennessee Medical Center
Dr. Jill Streams, Vanderbilt University Medical Center
Dr. Robert Winfield, The University of Kansas Hospital (The University of Kansas Medical Center)
Dr. Toby Enniss, University of Utah Health
Dr. Jeffrey Johnson, Henry Ford Health
Dr. Andrew Benjamin, The University of Chicago
Dr. Christine Trankiem, MedStar Health
Dr. Tanya Egodage, Cooper University Health Care
Dr. Kenji Inaba, Los Angeles General Medical Center
Dr. Ashley Meagher, IU Indiana
Dr. Jason W. Smith, University of Louisville
Dr. Adrian Ong, Reading Hospital
Dr. Luis G. Fernandez, University of Texas Health Tyler
Dr. Joseph Cuschieri, San Francisco General Hospital and Trauma Center (Zuckerberg San Francisco General Hospital and Trauma Center)
Dr. Zachary Warriner, UK Healthcare
Funding
The TAP trial, including the work reporting in this article, was funded by CSL Behring. The funder did not have a role in the conceptualization, design, data collection, or analysis.
Author information
Authors and Affiliations
Consortia
Contributions
Stephens, Carroll-Ledbetter, Griffin and Jansen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Stephens, Griffin, Jansen. Acquisition and analysis of data: Stephens, Carroll-Ledbetter, Duckert, Nelson, Griffin, Jansen. Interpretation of data: Stephens, Carroll-Ledbetter, Griffin, Jansen, McClintock, Goldkind, Gelinas, Higley, Joseph, Holcomb. Statistical analysis: Griffin. Drafting of the manuscript: Stephens, Jansen. Critical revision of the manuscript for important intellectual content: Stephens, Carroll-Ledbetter, Duckert, Nelson, Rodgers, Griffin, Suen, Casey, Sloan, McClintock, Goldkind, Gelinas, Higley, Joseph, Holcomb, Jansen.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethical approval for the community consultation and public disclosure was granted by Advarra Institutional Review Board (https://www.advarra.com/review-services/institutional-review-board-services/; Advarra, Inc.; Columbia, Maryland, USA). The community consultation and public disclosure, as well as the subsequent trial (although not reported in this manuscript) adhered to the Declaration of Helsinki.
The results reported in this manuscript are those of the community consultation and public disclosure performed in preparation for the trial, rather than the results of the trial itself, and therefore did not require consent, as determined by the Institutional Review Board, Advarra (https://www.advarra.com/review-services/institutional-review-board-services/; Advarra, Inc.; Columbia, Maryland, USA).
Consent for publication
Not applicable.
Competing Interests
Stephens received grants from CSL Behring during the conduct of the study; personal fees from CelCor Therapeutics and Infrascan outside the submitted work; and grants from Infrascan outside the submitted work. Rodgers received grants from CSL Behring during the conduct of the study. Suen was an employee of CSL Behring and outside the submitted work. Casey was an employee of CSL Behring during the conduct of the study and outside the submitted work. Holcomb received equity from Decisio Health, QinFlow, Zibrio, Hemostatics, and CCJ Medical and personal fees from Aspen and WFIRM outside the submitted work. Jansen received grants and personal fees from CSL Behring during the conduct of the study; personal fees from Octapharma, Infrascan, and Arsenal Medical outside the submitted work; and grants from Infrascan, RevMedX, National Institutes of Health, Department of Defense, and outside the submitted work. No other disclosures were reported.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information

12910_2026_1394_MOESM2_ESM.png (download PNG )
Supplementary Material 2. Supplementary Figure 1 Probability of a “yes”, “no”, or “I don’t know” response (on y-axis) to the four questions (in rows), with reference to age and household income. The first column of graphs demonstrates the relationship between age, household income, and the probability of a “yes” response. The second column of graphs demonstrates the relationship between age, household income, and the probability of a “no” response. The third column of graphs demonstrates the relationship between age, household income, and the probability of a “no” response. Darker colors indicate a lower probability. The upper part of the graph shows the data three-dimensionally, and the lower part simply as a “heat map”.

12910_2026_1394_MOESM3_ESM.png (download PNG )
Supplementary Material 3. Supplementary Figure 2. Probability of a “yes”, “no”, or “I don’t know” response (on y-axis) to the four questions (in rows), with reference to age and educational attainment. The first column of graphs demonstrates the relationship between age, educational attainment, and the probability of a “yes” response. The second column of graphs demonstrates the relationship between age, educational attainment, and the probability of a “no” response. The third column of graphs demonstrates the relationship between age, educational attainment, and the probability of a “no” response. Darker colors indicate a lower probability. The upper part of the graph shows the data three-dimensionally, and the lower part simply as a “heat map”.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Stephens, S.W., Carroll-Ledbetter, C., Duckert, S. et al. Social and demographic predictors of willingness to participate in an exception from informed consent trial. BMC Med Ethics 27, 65 (2026). https://doi.org/10.1186/s12910-026-01394-7
Received:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1186/s12910-026-01394-7

